Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
De parte del Oráculo:
Nov. 21 (Bloomberg) -- Threshold Pharmaceuticals Inc (THLD US) was rated new
"Buy" at Brean Murray by equity analyst Gene Mack. The 12-month target price is
$15.00 per share.
Consulta los Mejores roboadvisors